vimarsana.com

Latest Breaking News On - Applied therapeutics - Page 8 : vimarsana.com

Applied Therapeutics Rallies After Announcing Private Placement Of Shares

Shares of Applied Therapeutics, Inc. (APLT) are surging more than 40 percent Wednesday morning after the clinical-stage biopharmaceutical company announced a private placement to the tune of $100 million.

Therapeutics incApplied therapeutics

Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round

Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

Dow jones company incDrug administrationDean sealApplied therapeuticsDow jones

Applied Therapeutics Rallies After Announcing Private Placement Of Shares

Shares of Applied Therapeutics, Inc. (APLT) are surging more than 40 percent Wednesday morning after the clinical-stage biopharmaceutical company announced a private placement to the tune of $100 million.

Therapeutics incApplied therapeutics

Critical Review: Allarity Therapeutics (NASDAQ:ALLR) versus Applied Therapeutics (NASDAQ:APLT)

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Applied Therapeutics (NASDAQ:APLT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation. Analyst Recommendations This is a summary of […]

United statesNew yorkAllarity therapeutics incTherapeutics incAllarity therapeuticsGet free reportApplied therapeuticsGiven applied therapeuticApplied therapeuticDetsamma investmentsAllarity therapeutics dailyNasdaq allrStock comparisonStock analysis

Live by the SORD: Applied Therapeutics looks to rare disease NDA

Based on positive phase III study data, Applied Therapeutics Inc. plans to take its CNS-penetrant aldose reductase inhibitor to the U.S. FDA to talk about an NDA for treating the rare disease sorbitol dehydrogenase (SORD) deficiency. SORD, a hereditary axonal neuropathy created by sorbitol dehydrogenase gene mutations, affects about 3,300 people in the U.S. and about 4,000 in Europe, according to Applied Therapeutics.

Therapeutics incApplied therapeuticsApplied therapeutics incAt 007Sorbitol dehydrogenase deficiencyRare diseaseNeurology psychiatricCharcot marie tooth diseaseDistal hereditary motor neuropathy

vimarsana © 2020. All Rights Reserved.